One company we have covered several times here is Mangoceuticals, Inc. (NASDAQ: MGRX), an up-and-coming Nasdaq small-cap launching disruptive products and services focused on the rapidly growing $31 billion men’s health and wellness marketplace.
The company’s co-founder and CEO, Jacob Cohen, was interviewed last week on the popular McNallie Money YouTube podcast. It’s worth checking out.
The interview segment does an excellent job of providing an in-depth sense of where this story is heading, and Mr. Cohen knocks it out of the park in terms of capturing why MGRX is such an interesting small-cap growth opportunity.
The Interview
Bryce McNallie begins by exploring how MangoRx was born, and how Mr. Cohen got involved. It turns out Cohen had been an investor in both healthcare and telemedicine, and he identified telemedicine as a major growth theme.
MangoRx was developed as a fresh angle on telemedicine targeting what Cohen saw as an extremely promising but very underserved niche: men’s wellness products developed for and marketed to a younger male demographic.
To target that market, Cohen says fresh messaging angles and humor have been key parts of the company’s strategy on the marketing side. This is exemplified by the company’s “Some things are better hard” viral video, which has millions of organic views, and its “Make American Hard Again” nationwide campaign, which includes the red hats and even a Trump impersonating street performer.
The interview ranges from there to exploring MangoRx’s ED products.
Original Mango (think: “Man, Go!”) offers a special formulation featuring the same active ingredient that powers Cialis™ (Tadalafil) in combination with other FDA approved ingredients to maximize efficacy. Those other ingredients are Oxytocin and L-Arginine—the former is a compound known as “the love hormone”, helping to foster intimacy and warmth, while the latter is an amino acid known to help increase blood flow.
And it’s all packaged in a rapidly dissolved orally absorbed tablet capable of producing results in 15 minutes, with effects lasting up to 36 hours.
However, just a few weeks ago, the company announced the upcoming release of its second Mango ED product leveraging its existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra™ delivered, like original Mango, in a rapidly dissolving mango-flavored tablet that activates and dissolves orally for immediate action.
The other interesting edge the company has put in place, as noted above, is its unique telemedicine platform. Mango is a prescription medication that must be approved by a physician. But the company has set up a telehealth infrastructure to aid in that process: After an individual has completed an online telehealth visit, MGRX’s network of medical providers will review and approve a prescription if medically appropriate, and then send the product immediately to the customer.
Cohen goes on to discuss the company’s recipe for success as being about its ability to gain an edge in three areas at once: Formula, Marketing, and Packaging.
This leads to a discussion of the company’s recent game-changing collaborations, including the GaS Network, Barstool Sports, Only Stans, Adam22, No Jumper. The company is finding its place in the mix with a target on non-traditional ad strategies where the key is its focus on outlets with a strong and proven appeal to a younger male demographic.
Toward the end of the interview, Cohen lays out an exciting vision for the future that includes new products, new strategies, new verticals—all targeting its wheelhouse in the men’s health and wellness space.
The interviewer, Bryce McNallie, makes a good point in closing that captures the essence of why this stock is so interesting: these folks are specializing in helping men live better, healthier, happier lives. That is a fundamentally underserved niche, which is good for its customers, but also good for its investors, as the competition barrier is relatively thin despite targeting a $31 billion marketplace.
Again, this interview piece is a terrific way to really understand the MGRX story and why this may be a powerful small-cap Nasdaq opportunity.
